Alnylam Pharmaceuticals (ALNY) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dr. Reddy's Laboratories (RDY) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 7.0% versus a loss of 67.0%. Over five years, RDY leads with a +18.2% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $12.41 billion), about 1.6 times the size.
On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (14.5x vs 22.5x for Dr. Reddy's Laboratories). Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Alnylam Pharmaceuticals does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | RDY |
|---|---|---|
| Share price | $143.82 | $14.89 |
| Market cap | $19.26B | $12.41B |
| 1-day change | -2.71% | +0.40% |
| YTD return | -63.83% | +6.05% |
| 1-year return | -67.04% | +7.05% |
| 5-year return | -23.72% | +18.19% |
| P/E ratio (TTM) | 7.26 | 41.36 |
| Forward P/E | 14.51 | 22.47 |
| EPS (TTM) | $19.80 | $0.36 |
| Dividend yield | 0.00% | 53.73% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $3.71B | $3.81B |
| Revenue growth (YoY) | +65.19% | +13.76% |
| Net income (latest FY) | $313.75M | $663.00M |
| Gross margin | 81.77% | 58.51% |
| Operating margin | 13.51% | 22.09% |
| Net margin | 8.45% | 17.40% |
| 52-week high | $479.79 | $15.67 |
| 52-week low | $143.40 | $11.36 |
| Distance from 52-week high | -70.02% | -4.98% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +101.10% | +0.20% |
| Average volume | 2.09M | 2.85M |
| Shares outstanding | 133.94M | 833.66M |
| Employees | 2,500 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RDY has outperformed ALNY by 74.1 percentage points over the past year.
- Dr. Reddy's Laboratories trades at a higher earnings multiple (41.4x vs 7.3x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (53.73% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +13.76%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
ALNY vs RDY FAQ
Which is bigger, Alnylam Pharmaceuticals or Dr. Reddy's Laboratories?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $12.41B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, ALNY or RDY?
RDY returned +7.05% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or RDY?
ALNY has the lower trailing P/E at 7.3, versus 41.4 for RDY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Alnylam Pharmaceuticals or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.
Are Alnylam Pharmaceuticals and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.